Introduction Platelets play a key role in the pathophysiology of acute coronary syndromes (ACS) and complications following percutaneous coronary intervention (PCI). Three classes of platelet-inhibiting drugs – aspirin, thienopyridines, and platelet glycoprotein (GP) IIb/IIIa inhibitors – are most commonly used for the prevention and treatment of disorders of arterial vascular thrombosis. 1 These anti platelet agents have different mechanisms of action. Aspirin inhibits the cyclooxygenase (COX)-1 enzyme, thereby blocking thromboxane A 2 (TXA 2 ) synthesis in platelets.